Peptibodies: A flexible alternative format to antibodies

Peptibodies or peptide-Fc fusions are an attractive alternative therapeutic format to monoclonal antibodies. They consist of biologically active peptides grafted onto an Fc domain. This approach retains certain desirable features of antibodies, notably an increased apparent affinity through the avidity conferred by the dimerization of two Fcs and a long plasma residency time. Peptibodies can be made in E. coli using recombinant technology. The manufacturing process involves fermentation and downstream processing, including refolding and multiple column chromatographic steps, that result in overall yields and quality suitable for commercial development. Romiplostim, marketed under the brand name Nplate®, is the first peptibody to be approved by the United States Food and Drug Administration and the European Medicines Agency and is indicated for the treatment of immune thrombocytopenic purpura. AMG 386, a peptibody antagonist to angiopoietins 1 and 2, is being evaluated in Phase 3 clinical testing in combination with chemotherapy in women with ovarian cancer. AMG 819, a peptibody targeting nerve growth factor for pain has also progressed to clinical trials. These peptibodies illustrate the versatility of the modality.

[1]  C. Gegg,et al.  Ligand-Binding Mass Spectrometry to Study Biotransformation of Fusion Protein Drugs and Guide Immunoassay Development: Strategic Approach and Application to Peptibodies Targeting the Thrombopoietin Receptor , 2010, The AAPS Journal.

[2]  J. T. Sullivan,et al.  Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand , 2004, Clinical pharmacology and therapeutics.

[3]  C. Begley,et al.  Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. , 2002, Blood.

[4]  J. Bussel,et al.  Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. , 2009, Blood.

[5]  J. George,et al.  AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. , 2006, The New England journal of medicine.

[6]  R. Kontermann.  Strategies to Extend Plasma Half-Lives of Recombinant Antibodies , 2012, BioDrugs.

[7]  Thomas Hartmann,et al.  Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. , 2004, Cancer cell.

[8]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[9]  M. Seidel,et al.  Nerve growth factor in rheumatic diseases. , 2010, Seminars in arthritis and rheumatism.

[10]  Gavin Thurston,et al.  Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system , 2009, Nature Reviews Molecular Cell Biology.

[11]  V. Broudy,et al.  AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. , 2004, Cytokine.

[12]  Klaus Graumann,et al.  Manufacturing of recombinant therapeutic proteins in microbial systems , 2006, Biotechnology journal.

[13]  A. Newland,et al.  Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside , 2010, British journal of haematology.

[14]  J. George,et al.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.

[15]  R. Herbst,et al.  Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Baccanari,et al.  Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. , 1997, Science.

[17]  L. Nguyen,et al.  Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody , 2010, Molecular Cancer Therapeutics.

[18]  B. Chong,et al.  Romiplostim or standard of care in patients with immune thrombocytopenia. , 2010, The New England journal of medicine.

[19]  J. Neal,et al.  AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. , 2010, Current opinion in molecular therapeutics.

[20]  P. Koumoutsakos,et al.  Tumorigenesis and Neoplastic Progression Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels , 2009 .

[21]  T. Boone,et al.  Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.

[22]  G. Molineux.  The development of romiplostim for patients with immune thrombocytopenia , 2011, Annals of the New York Academy of Sciences.

[23]  H. Lowman,et al.  Bacteriophage display and discovery of peptide leads for drug development. , 1997, Annual review of biophysics and biomolecular structure.

[24]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[25]  J. Verweij,et al.  The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. , 2006, European journal of cancer.